Genentech

FiercePharmaAsia—BeiGene’s short attack; Sumitomo-Roivant deal; Roche-JHL settlement | FiercePharma | 9/13/2019

A short seller claims BeiGene falsified Chinese sales of its drugs licensed from Celgene, but the biotech called the allegations “wild speculations.” Sumitomo Dainippon will pay $3 billion upfront for five of Roivant Sciences’ companies—and for a future after Latuda loses U.S. exclusivity in 2023. Roche’s Genentech settled with Taiwan’s JHL Biotech over alleged trade secrets theft, though the individuals involved may not be so lucky. And more. 1 …

Genentech’s Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer – Company Announcement - FT.com | Financial Times | 9/13/2019

New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment - - Data will be submitted to health authorities around the world, including the U.S. Food and Drug Administration and European Medicines Agency - - Results will be presented at an upcoming medical meeting - SOUTH SAN FRANCISCO, Calif. –(BUSINESS WIRE)–Sep. 13, 2019– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY …

Follow Genentech:    

Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis – Company Announcement - FT.com | Financial Times | 9/13/2019

… analysis of Phase IIIb study shows 87% of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to Ocrevus – – Separate analysis from same study showed greater patient satisfaction with Ocrevus after one year on treatment – – More than 120,000 people have been treated with Ocrevus globally, in clinical trial and real-world settings; data continue to show a consistent and favorable benefit-risk …

[download][email protected]@ Genentech The Beginnings Of Biotech Synthesis book ^^Full_Books^^ 846 | 9/13/2019

Genentech The Beginnings Of Biotech Synthesis book Download at = https://ebooklibraryharis84j8ed.blogspot.com/022604551X Genentech The Beginnings Of Biotech Synthesis book pdf download, Genentech The Beginnings Of Biotech Synthesis book audiobook download, Genentech The Beginnings Of Biotech Synthesis book read online, Genentech The Beginnings Of Biotech Synthesis book epub, Genentech The Beginnings Of Biotech Synthesis book pdf full ebook, Genentech The Beginnings Of Biotech Synthesis book amazon, Genentech The Beginnings Of Biotech …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Benzinga | 9/13/2019

SAN DIEGO , Sept. 13, 2019 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta ® ) and trastuzumab (Herceptin ® ) for subcutaneous administration using Halozyme’s ENHANZE ® drug delivery technology in combination with intravenous …

Genentech’s Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer | Benzinga | 9/13/2019

… is exposed to Perjeta during pregnancy or becomes pregnant while receiving Perjeta or within seven months following her last dose of Perjeta in combination with Herceptin, she is encouraged to report Perjeta exposure to Genentech at (888) 835-2555. Other possible serious side effects Perjeta should not be used in patients who are allergic to pertuzumab or to any of the ingredients in Perjeta. Infusion-related reactions: Perjeta is a medicine …

Halozyme: Genentech Reports Positive Outcome From Phase III Study Using ENHANZE | Markets Insider | Business Insider | 9/13/2019

RTTNews) - Halozyme Therapeutics, Inc. (HALO) said the phase III FeDeriCa trial, a global study conducted by Genentech using combination of pertuzumab and trastuzumab using Halozyme’s ENHANZE drug delivery technology, met its primary endpoint. Halozyme said the results of the study is an important development for the ENHANZE technology. Helen Torley, CEO, said: “This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing …

Oncology Small Molecule Drugs Market Report Examines Latest Trends and Key Drivers Supporting Growth through 2029 | 9/13/2019

… new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an important acquisition beefing up the former’s oncology offerings with two marketed drugs – BRAF inhibitor Braftovi, and MEK inhibitor Mektovi. These two drugs have …

Global Ranibizumab Market 2019 by Company, Regions, Type and Application, Forecast to 2024 | 9/13/2019

… countries, product types and end industries; this report analyzes the top players in global market, and splits the Ranibizumab market by product type and applications/end industries. Market Segment by Companies, this report covers - Genentech Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

SAN DIEGO, Sept. 13, 2019 /PRNewswire/ – Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme’s ENHANZE® drug delivery technology in combination with intravenous …

Medical Science Liaison/Sr. - Neuroscience (WA, OR, ID, MT, AK, WY) | 9/13/2019

… of America The Position Purpose: The Medical Science Liaison (MSL) is responsible for providing external and internal customers with clinical, scientific, and health economic information related to the appropriate utilization of products in the Genentech portfolio and with more general information about the relevant therapeutic area and disease state. This field-based position will proactively build healthcare provider, population health decision maker, and patient support, by using an approach that …

Trastuzumab Appeals Update | 9/13/2019

Last week, several briefs were filed in Federal Circuit appeals relating to trastuzumab biosimilars: Trastuzumab IPR Appeals On September 3, 2019, the USPTO submitted responsive appellate briefs in Federal Circuit appeals from IPR final written decisions regarding two patents related to methods of treating HER2+ cancer with trastuzumab (Cases Nos. 19-1263 , 19-1265 , 19-1267 , and 19-1270 ). Genentech had argued in its opening briefs that the PTAB erred as a matter of …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta And Herceptin Using Halozyme’s Enhanze Drug Delivery Technology | 9/13/2019

New Subcutaneous Fixed-dose Combination Significantly Reduced Administration Time - - Data to be Submitted to Health Authorities including the U.S. Food and Drug Administration and European Medicines Agency - SAN DIEGO, Sept. 13, 2019 / / – Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The …

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer | PR Newswire | 9/13/2019

… 0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019 , and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation …

Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum | PR Newswire | 9/12/2019

TOKYO and LONDON , Sept. 12, 2019 /PRNewswire/ – Sosei Group Corporation (“the Company”; TSE: 4565) today held an Investor R&D Event in Tokyo, Japan , discussing how the integration of its proprietary StaR® technology and approach to AI and machine learning in structure-based drug discovery at its new state-of-the-art R&D center, positions the Company well to continue delivering high-quality drug candidates, strategic partnerships and strong …

Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder – Company Announcement - FT.com | Financial Times | 9/12/2019

… and in combination with baseline therapy, suggest that IL-6 inhibition may be an effective therapeutic approach for NMOSD. The Phase III clinical development program for satralizumab includes two studies: SAkuraStar and SAkuraSky. About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche . The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the …

Genentech’s Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy – Company Announcement - FT.com | Financial Times | 9/12/2019

… Product Development. “These findings reinforce the potential of Tecentriq to play an important role in the treatment of multiple forms of lung cancer, and we look forward to discussing these data with health authorities.” Genentech will now submit these data to global health authorities, including the FDA and EMA, and will discuss how best to bring this option to patients as quickly as possible. These data will be presented at …

NI Research Publishes Annual Review of Alzheimer’s Therapeutics | PR Newswire | 9/12/2019

… Cortexyme and Rodin Therapeutics each have a Company Review . Sidebars include coverage of the current state of the AD Biomarker art and an overview of the POC timelines for major AD programs. Commentary covers Novartis ‘ damaging and untimely omissions around Zolgensma; the impending clash between Harmony and Jazz over narcolepsy; and Vanda ‘reaping what they sowed’ from the FDA. The 83-page issue also includes a full review of Frontotemporal …

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 | PRWeb | 9/12/2019

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 Share Article Superior Controls will attend the 28th annual International Society of Pharmaceutical Engineering (ISPE) Boston Area Chapter Product Show at Gillette Stadium in Foxborough, MA September 18, 2019 from 10:00 am - 5:00 pm SEABROOK, N.H. (PRWEB) September 12, 2019 Superior Controls, Inc. , a leading Life …

Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder | Benzinga | 9/12/2019

… and in combination with baseline therapy, suggest that IL-6 inhibition may be an effective therapeutic approach for NMOSD. The Phase III clinical development program for satralizumab includes two studies: SAkuraStar and SAkuraSky. About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the …

Biotech

[download][email protected]@ Genentech The Beginnings Of Biotech Synthesis book ^^Full_Books^^ 846 | 9/13/2019

Genentech The Beginnings Of Biotech Synthesis book Download at = https://ebooklibraryharis84j8ed.blogspot.com/022604551X Genentech The Beginnings Of Biotech Synthesis book pdf download, Genentech The Beginnings Of Biotech Synthesis book audiobook download, Genentech The Beginnings Of Biotech Synthesis book read online, Genentech The Beginnings Of Biotech Synthesis book epub, Genentech The Beginnings Of Biotech Synthesis book pdf full ebook, Genentech The Beginnings Of Biotech Synthesis book amazon, Genentech The Beginnings Of Biotech

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 | PRWeb | 9/12/2019

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 Share Article Superior Controls will attend the 28th annual International Society … nationally with industry leaders such as Pfizer, Biogen, GE Healthcare, Genentech, Gilead and more. Superior Controls and Banks Integration Group have four engineering offices located in Seabrook, New Hampshire, Albany, New York, Vacaville, California and

Food and Drug Administration

Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS | Business Wire | 9/4/2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Sep 4, 2019– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data across its neuroscience portfolio will be presented at the … for the treatment of NMO and NMOSD by the U.S. Food and Drug Administration in December 2018. About Ocrevus ® (ocrelizumab) Ocrevus is the first and only therapy approved for both RMS (including clinically isolated syndrome

Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS – Company Announcement - FT.com | Financial Times | 9/4/2019

… of more than six years show reduction of disability progression in relapsing and primary progressive MS – – Breadth of data reinforce Genentech’s commitment to following the science to gain a better understanding of complex nervous system … for the treatment of NMO and NMOSD by the U.S. Food and Drug Administration in December 2018 . About Ocrevus ® (ocrelizumab) Ocrevus is the first and only therapy approved for both RMS (including clinically isolated syndrome …

American Society of Clinical Oncology

Roche drug is third to win biomarker-driven cancer approval from FDA | MedCity News | 8/16/2019

… testing to bring this new treatment option to patients who are waiting,” said Sandra Horning, chief medical officer at Roche’s Genentech division, in a statement. “Rozlytrek is the first FDA-approved treatment that selectively targets … oncologist Dr. Douglas Hawkins said in an interview at the American Society of Clinical Oncology in June that whereas one can often guess whether a pediatric tumor carries an NTRK fusion based on what kind …

The Corporate Reputation of Pharma in 2018: Cancer Patient Perspective Survey - ResearchAndMarkets.com | Business Wire | 8/14/2019

… industry’s drop in corporate reputation among rare-cancer patient groups may seem surprising, given a January 2019 announcement by the American Society of Clinical Oncology (ASCO) that research to treat rare cancers comprises the Advance … all respondent cancer patient groups): Janssen, Novartis, Pfizer, and Roche/Genentech. Janssen was ranked overall 1st out of 36 companies for corporate reputation in 2018 by the 139 respondent cancer patient groups familiar with the …

Big Pharma

BioNTech files for IPO after investor reneges on $88M promise | FierceBiotech | 9/10/2019

Genentech, Sanofi and Genmab. Germany’s BioNTech began life focused on mRNA, putting it in similar territory to Moderna, but has branched out in recent years, building a pipeline of assets spanning multiple modalities including cell therapies and antibodies. Along the way, BioNTech has raised vast sums of money in private rounds, some of it from a growing list of Big Pharma partners including Eli Lilly, Pfizer and Sanofi. Now, BioNTech …

This Startup Used AI To Design A Drug In 21 Days | Forbes | 9/3/2019

… activity is being investigated as a possible therapy. The challenge was based on recently published research from a team at Genentech, which had taken about 8 years to identify promising DDR1 kinase inhibitors. An overview … that this paper will remove a lot of skepticism in big pharma,” he says …

ACA

MotionHall Hires Erin O’Halloran as VP of Commercial Operations | PRWeb | 8/23/2019

… consumer behavior, and problem-solving with critical-thinking and practicality. While at Merck, and later Pfizer, she worked directly with Academic Leaders, Medical Residents, and Fellows to support and educate them on anti-infective medications … most successful pharma and technology industry veterans, including advisors from Genentech, Veeva, Thomson Reuters Life Sciences, and Palantir. We are backed by First Star Ventures and Village Global, a catalyst fund backed by Bill Gates …

Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors | Globe Newswire | 8/12/2019

… disease and frontotemporal dementia.” Dr. Yaffe has received numerous awards for her groundbreaking contributions to the field including the American Academy of Neurology Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Diseases, a prestigious … CFO of Facebook; Lou J. Lavigne Jr., former CFO of Genentech; Richard Scheller, former EVP of research at Genentech and former CSO of 23andMe; Terry McGuire, Polaris Venture Partners. About Alector Alector is a clinical …

NIH

Draft Pelosi plan offer carrots to both Trump and … | Politico | 9/10/2019

Presented by Genentech With help from Allie Bice — A draft of Pelosi’s drug pricing plan is out, with 250 drugs targeted for negotiation. — BIO CEO : We’re not interested in trading Part D inflation caps for … Savings from the lower-priced drugs would be directed to NIH to develop new medicines. The maximum price negotiated for the drugs must be no more than 1.2 times of the average price in six

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Core Grant P30 CA008748 (JEL, JHF, IJD and DHA) . This work was also supported by the National Institutes of Health (NIH) grant P30 EY010572 and by unrestricted departmental funding from Research to Prevent Blindness (AHS … personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted work. AHS reports personal fees from Castle Biosciences, Inc, outside the submitted work. ABD reports grants from Research to Prevent Blindness …

Biosimilars

Trastuzumab Appeals Update | 9/13/2019

Last week, several briefs were filed in Federal Circuit appeals relating to trastuzumab biosimilars: Trastuzumab IPR Appeals On September 3, 2019, the USPTO submitted responsive appellate briefs in Federal Circuit appeals from IPR final written decisions regarding two patents related to methods of treating HER2+ cancer with trastuzumab (Cases Nos. 19-1263 , 19-1265 , 19-1267 , and 19-1270 ). Genentech had argued in its opening briefs that the PTAB erred as a matter of …

Genentech Is Second Biologic Titan To Resolve Trade Secret Suit; Former Employees Still On Hook | 9/9/2019

Genentech Is Second Biologic Titan To Resolve Trade Secret Suit; Former Employees Still On Hook 08 Sep 2019 Brenda Sandburg @brendasandburg Executive Summary Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely. Existing Subscriber? Sign in to continue reading. Genentech reaches initial agreement with JHL Biotech in biosimilar trade secret theft case Table Your …

Medicare

Validea’s Top Five Healthcare Stocks Based On Joel Greenblatt - 8/18/2019 - Nasdaq.com | 8/18/2019

… multiple sclerosis ( MS ), FUMADERM severe plaque psoriasis and SPINRAZA spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN non-Hodgkin’s … business. It arranges healthcare services for persons served by Medicaid, Medicare, the Children’s Health Insurance Program (CHIP) and the Marketplace, and products to assist government agencies in their administration of the Medicaid program. As of …

Medical Research

Wednesday, September 11, 2019 | Kaiser Health News | 9/11/2019

Genentech when they did the research. (9/10) Nature: Immune-Cell Pioneers Win Prestigious Lasker Medical Award Two scientists who discovered the roles of key immune cells have won one of the 2019 Lasker medical-research awards — prizes often dubbed the American Nobels. Immunologists Jacques Miller, at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and Max Cooper, at Emory University in Atlanta, Georgia, will split the …

Lasker Foundation Announces 2019 Lasker Awards For Basic And Clinical Medical Research And Public Service | PR Newswire | 9/10/2019

NEW YORK The Lasker Foundation today announced the winners of its 2019 Lasker Awards: Max D. Cooper from Emory University and Jacques Miller from the Walter and Eliza Hall Institute of Medical Research will receive the Albert Lasker Basic Medical Research Award; H. Michael Shepard , formerly of Genentech, Dennis J. Slamon from the University of California, Los Angeles and Axel Ullrich from the Max Planck Institute of Biochemistry (also formerly …

National Institutes of Health

Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017 | BMJ | 8/23/2019

… Cancer Center Support Grant/Core Grant P30 CA008748 (JEL, JHF, IJD and DHA) . This work was also supported by the National Institutes of Health (NIH) grant P30 EY010572 and by unrestricted departmental funding from Research … personal fees from Ipsen, personal fees from Pfizer, grants from Genentech, outside the submitted work. AHS reports personal fees from Castle Biosciences, Inc, outside the submitted work. ABD reports grants from Research to Prevent Blindness …

Biotech leaders speak out against dismissals of Chinese scientists - FierceBiotech (1 visits) | 8/22/2019

China’s theft of intellectual property from the U.S. and other countries isn’t new—remember the Genentech scientists and the GlaxoSmithKline researchers who funneled trade secrets to associates in China and Taiwan? But a government crackdown … 150 industry leaders. The letter comes one year after the National Institutes of Health started a campaign to enforce rules requiring that scientists receiving its grants report their foreign ties. Since August 2018, the agency

Novartis

Oncology Small Molecule Drugs Market Report Examines Latest Trends and Key Drivers Supporting Growth through 2029 | 9/13/2019

Novartis Ag, Astrazeneca, Genentech, Pfizer, and Abbvie, accounting for ~47% market value share. These players are emphasizing strong regional presence, robust R&D, new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an …

Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum | PR Newswire | 9/12/2019

Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK . “Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit https://www.soseiheptares.com/ LinkedIn: @soseiheptaresco Twitter: @soseiheptaresco YouTube: @soseiheptaresco Enquiries: Sosei Heptares Investor Relations and Corporate Communications Shinichiro Nishishita, Mai Kurokawa +81-(0)-3-5210-3399 …

Pfizer

Oncology Small Molecule Drugs Market Report Examines Latest Trends and Key Drivers Supporting Growth through 2029 | 9/13/2019

Genentech, Pfizer, and Abbvie, accounting for ~47% market value share. These players are emphasizing strong regional presence, robust R&D, new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an important acquisition beefing …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

… biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated … value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information …

Merck

Real-World Data Favor Doublets in Esophageal/Gastric Cancer | Medscape | 9/3/2019

… were each given to 10% of the cohort. The most commonly used regimen in this Dutch cohort was capecitabine ( Xeloda, Genentech) plus oxaliplatin ( Eloxatin, Sanofi-Aventis), received by 21% of patients, followed by the triplet … received research funding from Bayer, Bristol-Myers Squib, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, and Roche. Several coauthors also have relationships with pharmaceutical companies, as detailed in the original article. Int J Cancer. Published …

Debbie’s Dream Foundation and Cleveland Clinic Florida to Host 1st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast | PR Newswire | 8/30/2019

Merck; Silver Sponsor Baptist Health; Bronze Sponsor Genentech; and National Supporting Sponsor Taiho Oncology. All lectures will be accessible on the DDF website at http://www.DebbiesDream.org/portal/ lecture-library . About Debbie’s Dream Foundation: Curing Stomach Cancer DDF is a 501(c)(3) non-profit organization dedicated to raising awareness about gastric cancer, advancing funding for research, and providing education and support internationally to patients, families, and caregivers. DDF seeks as …

Bristol-Myers

Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors | PR Newswire | 9/4/2019

… of phosphoinositide-3-kinase (PI3K)-gamma. Infinity initiated MARIO-3, a Phase 2 multi-arm study in collaboration with Roche/Genentech evaluating IPI-549 in combination with Tecentriq ® and Abraxane ® (nab-paclitaxel) in front-line … future events or otherwise. Opdivo ® is a registered trademark of Bristol-Myers Squibb. Tecentriq ® and Avastin ® are registered trademarks of Roche. Doxil ® is a registered trademark of Alza Corporation. Contact Jayne Kauffman , Infinity Pharmaceuticals, Inc …

Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors | Markets Insider | Business Insider | 9/4/2019

… of phosphoinositide-3-kinase (PI3K)-gamma. Infinity initiated MARIO-3, a Phase 2 multi-arm study in collaboration with Roche/Genentech evaluating IPI-549 in combination with Tecentriq ® and Abraxane ® (nab-paclitaxel) in front-line … future events or otherwise. Opdivo ® is a registered trademark of Bristol-Myers Squibb. Tecentriq ® and Avastin ® are registered trademarks of Roche. Doxil ® is a registered trademark of Alza Corporation. Contact Jayne Kauffman , Infinity Pharmaceuticals, Inc …

Bristol-Myers Squibb

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

… biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated … leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com . Halozyme Safe …

Biogen

NI Research Publishes Annual Review of Alzheimer’s Therapeutics | PR Newswire | 9/12/2019

… first report ( AbbVie ‘s mAb in PSP) was negative, this does not necessarily predict the outcome from other trials, with Biogen ‘s mAb trial looming large towards year-end. The neuroimmunological space has started to … Sciences, Cognition Therapeutics, Cortexyme, Denali, Eisai, EIP Pharma, E-Scape, Genentech, Grifols, Intra-Cellular, Ionis, JNJ, Karuna, Klogene, Lilly, Lundbeck, Novartis, Oryzon, ProMIS, Roche, Syndesi, Takeda, TauRx, and Voyager . Cortexyme and Rodin Therapeutics each have …

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 | PRWeb | 9/12/2019

Biogen, GE Healthcare, Genentech, Gilead and more. Superior Controls and Banks Integration Group have four engineering offices located in Seabrook, New Hampshire, Albany, New York, Vacaville, California and South San Francisco, California. For more information, visit Superior Controls’ website , LinkedIn , Facebook and Twitter . Share article on social media or email: View article via …

AbbVie

Oncology Small Molecule Drugs Market Report Examines Latest Trends and Key Drivers Supporting Growth through 2029 | 9/13/2019

Genentech, Pfizer, and Abbvie, accounting for ~47% market value share. These players are emphasizing strong regional presence, robust R&D, new launches, and diverse offerings to stay ahead of the competition in oncology small molecule drugs market, which compels companies to enter strategic collaborations with recognized biopharma companies. For instance, recently in June 2019, Pfizer announced the decision to buy the oncology specialist Array BioPharma, marking an important acquisition beefing …

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s Enhanze® Drug Delivery Technology | Business & Finance | manchestertimes.com | PR Newswire | 9/13/2019

… biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated … partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com …

Celgene

FiercePharmaAsia—BeiGene’s short attack; Sumitomo-Roivant deal; Roche-JHL settlement | FiercePharma | 9/13/2019

A short seller claims BeiGene falsified Chinese sales of its drugs licensed from Celgene, but the biotech called the allegations “wild speculations.” Sumitomo Dainippon will pay $3 billion upfront for five of Roivant Sciences’ companies—and for a future after Latuda loses U.S. exclusivity in 2023. Roche’s Genentech settled with Taiwan’s JHL Biotech over alleged trade secrets theft, though the individuals involved may not be so lucky. And more. 1 …

Real-World Data Favor Doublets in Esophageal/Gastric Cancer | Medscape | 9/3/2019

… were each given to 10% of the cohort. The most commonly used regimen in this Dutch cohort was capecitabine ( Xeloda, Genentech) plus oxaliplatin ( Eloxatin, Sanofi-Aventis), received by 21% of patients, followed by the triplet … Laarhoven has served as a consultant for Bristol-Myers Squibb, Celgene, Lilly, and Nordic and has received research funding from Bayer, Bristol-Myers Squib, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, and Roche. Several coauthors …

GlaxoSmithKline

Playing the pharma-to-biotech executive shuffle: The lure of raw science | FierceBiotech | 8/27/2019

… by pharmas, but many of the biggest-selling and innovative drugs have come from biotech (Gilead and Pharmasset, Roche and Genentech, to name but a few), and I couldn’t help but think that pharma struggled … Pharmas, including: Sanofi, AstraZeneca, Roche, Gilead Sciences, Novartis, Amgen and GlaxoSmithKline, with a few also coming out of the FDA and into the “dark side,” as many hope new faces and new ideas will bring …

Allergan

Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum | PR Newswire | 9/12/2019

… build a better life for patients, together with an update of the Company’s most advanced programs, including partnered programs with Allergan and AstraZeneca, and in-house programs mGlu5, SSTR5, CGRP and GPR35. Presentations and Video … cancer (with AstraZeneca). Our additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK . “Sosei Heptares” is …

PM360 Announces 2019 Trailblazer Award Finalists | PR Newswire | 8/20/2019

… Manager, Digital Myeloma Marketing Lead, Celgene Corporation Sam Candler , Marketing Manager II, Women’s Health, AbbVie Debra Hagan , Director, CNS Marketing, Allergan Robert Taylor , Senior Director, Marketing, Relypsa, a Vifor Pharma Group Company Sara Zwicker , MBA … Epidiolex Marketing, Greenwich Biosciences Respiratory: Jenn Etheridge , Senior Marketing Manager, Genentech Women’s Health: Eric Nelson , Marketing Director, Women’s Health, AbbVie INITIATIVE FINALISTS APP/DIGITAL SOLUTION OR SUITE “Being Patient: A Multiple Myeloma Experience” (Takeda Oncology …

Goldman Sachs

Genentech’s Deal Spree: Brainstorm Health | Fortune | 7/17/2019

… outstanding coverage of the equally-outstanding Fortune Brainstorm Tech conference currently taking place in Aspen. And a note below on Genentech’s “hat trick” of deals. Read on for the day’s news, back with much more … Isn’t Worried About Battling Chief Rival Microsoft , by Aaron Pressman Goldman Sachs CEO David Solomon Says the Company Is Doubling Down on Diversity and Inclusion , by Christopher Tkaczyk Commentary: Only Regulation Can Jump-Start Competition …

Adaptive Biotechnologies soars more than 100% on its first day | Nasdaq | 6/28/2019

Genentech and Microsoft. It is close to ramping up its newer immunoSEQ tests, and also has a preclinical drug development program. Adaptive raised $300 million by offering 15 million shares at $20, above the range of $18 to $19. It listed on the Nasdaq under the symbol ADPT. Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Cowen and Guggenheim Securities acted as lead managers on the deal. The article Adaptive Biotechnologies …

Biogen Idec

Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair | Business & Finance | heraldchronicle.com | PR Newswire | 6/24/2019

… engineering and rational design to create next-generation oncology therapeutics, today announced that Connie Matsui, retired Executive Vice President of Biogen Idec, has been appointed as Chair of Sutro’s Board of Directors. In joining the … of rituximab (tradenames: Rituxan®, MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells …

Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair | Markets Insider | Business Insider | 6/24/2019

… engineering and rational design to create next-generation oncology therapeutics, today announced that Connie Matsui , retired Executive Vice President of Biogen Idec, has been appointed as Chair of Sutro’s Board of Directors. In joining the … of rituximab (tradenames: Rituxan®, MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells …

Merrill Lynch

Adaptive Biotechnologies soars more than 100% on its first day | Nasdaq | 6/28/2019

Genentech and Microsoft. It is close to ramping up its newer immunoSEQ tests, and also has a preclinical drug development program. Adaptive raised $300 million by offering 15 million shares at $20, above the range of $18 to $19. It listed on the Nasdaq under the symbol ADPT. Goldman Sachs, J.P. Morgan, BofA Merrill Lynch, Cowen and Guggenheim Securities acted as lead managers on the deal. The article Adaptive Biotechnologies …

Adaptive Biotechnologies IPO: Five things to know - MarketWatch | 6/27/2019

Merrill Lynch, Cowen, Guggenheim Securities, William Blair and BTIG. Adaptive is putting together a massive database of hard-to-obtain information on the immune system that it hopes researchers and clinicians will use to build therapies for different diseases. The 10-year-old company has partnerships with Microsoft Corp. MSFT, +0.16% and Roche Holding Ltd.’s RHHBY, +0.19% Genentech. Here are five things to know about Adaptive Biotechnologies. Adaptive is …

Redmile Group

BioNTech raises $325M series B round to advance cancer pipeline | FierceBiotech | 7/9/2019

Genentech. That changed early in 2018 when BioNTech raised $270 million in a Redmile Group-led series A round. Now, BioNTech has raised $325 million in a round led by Fidelity Management & Research Company. Other existing investors including Redmile and the Struengmann Family Office contributed to the series B round, but two-thirds of the cash came from new investors. BioNTech will use the cash to build on the work …

IGM Biotherapeutics grabs $102M to push bispecific into the clinic | FierceBiotech | 7/9/2019

… bispecific antibody slated to start clinical trials by the end of the year. The capital, garnered from the likes of Redmile Group Janus Henderson Investors, Vivo Capital and Haldor Topsøe Holding, will help IGM build … a hiring spree in the past year, picking up Roche/Genentech veteran Daniel Chen, M.D., Ph.D., as its chief medical officer, longtime cancer researcher Wayne Godfrey to head up clinical development and Misbah Tahir, who’s …

New Enterprise Associates

VC-backed Pionyr names Levey as SVP and chief business officer | PE Hub | 8/27/2019

… officer. Previously, Levey worked at Tempest Therapeutics where she was vice president and chief business officer. Pionyr’s backers included OrbiMed, New Enterprise Associates, Sofinnova, SV Health Investors, Vida Ventures, Trinitas Capital, Mission Bay Capital and … player in early antibody phage-display technology platforms, formerly at Genentech, and is now head of protein engineering and antibody discovery at the University of Toronto. PIONYR is exploiting novel target discovery and antibody generation …

Live Long And Prosper: How Anne Wojcicki’s 23andMe Will Mine Its Giant DNA Database For Health And Wealth | Forbes | 6/6/2019

New Enterprise Associates and Genentech, 23andMe launched its first product in November 2007. The spit test cost $999 . Customers learned about their ancestry, their likelihood of going bald and their risk for some common health conditions like heart disease. The company skirted FDA regulations by advertising itself as a fun way for people to get insight into their DNA, rather than as a medical tool. At the time, it cost …

ARCH Venture Partners

Maze Therapeutics Appoints Drug Development Expert Richard Scheller, Ph.D., to its Board of Directors | Business & Finance | manchestertimes.com | Business Wire | 7/9/2019

… head of therapeutics and chief scientific officer at 23andMe. Prior to his role there, Dr. Scheller spent 14 years at Genentech where he was executive vice president of research and early development. He served on … launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Maze is based in South San Francisco. For more information …

Cell Encapsulation Markets 2019-2023: Current Market Landscape and the Future Potential of Encapsulated Cell Therapies and Affiliated Technologies | PR Newswire | 5/29/2019

… Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure Pharma Amgen Amphera AMVALOR Anhui Kedgene Biotechnology ANI Pharmaceuticals Anterogen apceth Biopharma Arbele ARCH Venture Partners Argos Therapeutics Asahi Glass Company ASAP Ventures Asset Management Partners Astellas Institute … FronTier Merchant Capital Gabriel Investments Gadeta Gamida Cell GC Cell Genentech Genextra Genzyme Georgia Institute of Technology GigaGen Giner Labs GlaxoSmithKline Global Cell Med Gloriana Therapeutics Glycostem Therapeutics Gradalis Graybug Vision Green Cross Greenwood Way …

Cambridge Innovation Capital

Genentech backs U.K. accelerator to help pre-A round startups | FierceMedicalDevices | 4/23/2019

Apr 23, 2019 4:07am With backing from Roche’s Genentech, Start Codon is now recruiting the first cohort of five companies. (Genentech) Genentech has backed Cambridge, U.K.-based life science accelerator Start Codon. The money will … bankroll Start Codon’s work. The accelerator also received funding from Cambridge Innovation Capital—a preferred investor of the University of Cambridge—and Babraham Bioscience Technologies (BBT). BBT manages and develops Babraham Research Campus, a hot

Leerink Partners

11 Biotech Stocks to Put on Your Radar Soon - Nasdaq.com | 5/30/2019

… gets the green light as a means of treating NMOSD - the FDA has set an “action date” of June 28 - Leerink Partners analyst Geoffrey Porges believes that could add $500 million to $700 million in … firm date has been given for its biosimilar version of Genentech-made cancer treatment Avastin, but the FDA’s decision on bevacizumab’s safety and effectiveness (in other words, its similarity) is expected to come sometime during …

US IPO Week Ahead: Two big biotechs lead 6-IPO week - Nasdaq.com | 12/1/2017

Cowen & Company SPAC formed by semiconductor veteran Avi Katz to acquire a TMT business. Check out our newly-released website, IPO Pro. Find out why institutional investors benefit from Renaissance Capital’s Pre-IPO Research for these IPOs. Follow us on Twitter ( @IPOtweet ) and register for our updates on the IPO market. 3 pre-bought healthcare deals: Denali Therapeutics ( DNLI ) is targeting $150 million (33% insider) at a $1.6 billion market …

William Blair

Adaptive Biotechnologies IPO: Five things to know - MarketWatch | 6/27/2019

William Blair and BTIG. Adaptive is putting together a massive database of hard-to-obtain information on the immune system that it hopes researchers and clinicians will use to build therapies for different diseases. The 10-year-old company has partnerships with Microsoft Corp. MSFT, +0.16% and Roche Holding Ltd.’s RHHBY, +0.19% Genentech. Here are five things to know about Adaptive Biotechnologies. Adaptive is betting on the power of …

Biotech IPOs For The Week Ahead | Markets Insider | Business Insider | 6/22/2019

William Blair & Company, L.L.C. and BTIG, LLC. Products: The Company’s first clinical diagnostic product, clonoSEQ, is the first test authorized by the FDA for the detection and monitoring of minimal residual disease (“MRD”) in patients with select blood cancers. The Company has a collaboration with Genentech for the research, development, marketing, promotion, distribution and sale of TCR-based cellular therapies for the treatment of cancer. Adaptive Bio’s total revenue in …

Biotechnology Value Fund

Syndax Pharmaceuticals: Binary Catalyst In Sight, Potential Participant In Lucrative Targeted Oncology Theme - Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) | Seeking Alpha | 6/19/2019

… could potentially replace Afinitor as standard of care. Another way to win was via combination studies with Merck’s Keytruda and Genentech’s Tecentriq. Perhaps even more importantly, I stated that management made a brilliant move when … that the company sold over 2 million shares directly to Biotechnology Value Fund. Figure 2: Pipeline (Source: corporate presentation ) UBS Global Healthcare Conference In CEO Briggs Morrison’s presentation at UBS Global Healthcare Conference, there were …

IPO Update: Peloton Therapeutics Aims For $150 Million IPO - Peloton Therapeutics, Inc. (Pending:PLTX) | Seeking Alpha | 5/14/2019

… registration statement Investors in Peloton include Eventide Asset Management, EcoR1 Capital, OrbiMed, Driehaus Capital Management, Vida Ventures, RA Capital Management, Biotechnology Value Fund, Curative Ventures, Foresite Capital, and Remeditex Ventures among others. Source: Crunchbase Market … BAYRY ) Bristol-Myers Squibb ( BMY ) Eisai ( OTCPK:ESALY ) Exelixis ( EXEL ) Genentech ( ROG ) Merck & Co ( MRK ) Novartis ( NVS ) Onyx Pharmaceuticals ( AMGN ) Pfizer ( PFE ) Prometheus Laboratories ( OTCPK:NSRGY ) Source: Sentieo Financial Status Peloton’s recent financial results are …

HCA

HIV/AIDS Drugs Market to Exhibit 6.1 % CAGR; Growing Emphasis on Research and Development of Efficient Drugs to Enable Growth, says Fortune Business Insights | Globe Newswire | 8/19/2019

Key companies covered in the HIV/AIDS Drugs Market Research report include ViiV Healthcare, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Theratechnologies Inc., Mylan Pharmaceuticals Inc., Genentech, Inc., and AbbVie Inc. August 19, 2019 04:00 ET Source: Fortune Business Insights Pune, The global Hiv/Aids Drugs Market is likely to derive growth form the increasing prevalence of the disease across the world. According …

Buoy Health raises $15 mln | PE Hub | 8/15/2019

… Buoy, of Boston, is a health platform that uses AI to provide clinical support to users when they have a healthcare concern. PRESS RELEASE BOSTON–( BUSINESS WIRE )– Buoy Health is an all-in-one platform … and organized the first J.P. Morgan Healthcare Conference. Apple, Google, Genentech, and Adobe are just a few of the companies, amongst others, Hambrecht has taken public. “I’ve seen many young companies grow to reach their …

Memorial Sloan Kettering

Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers | PR Newswire | 8/6/2019

… European Investment Bank Evaxion Biotech F-Prime Capital Fidelity Investments Flow Pharma Forbion Foresite Capital Franklin Advisers Frazier Healthcare Partners Genentech Geneos Therapeutics Genocea Biosciences Georgetown University GlobeImmune Google Ventures Gradalis Grey Wolf Therapeutics Gritstone … Association MD Anderson Cancer Center Medigene MedImmune Meir Medical Center Memorial Sloan Kettering Cancer Center Merck Meusinvest Mie University Miller Value Partners Miracle Light Incubator Moderna Therapeutics Moffitt Cancer Center Morningside Group MSD Partners NantBioScience …

Lymphoma Research Foundation to Honor Leading Lymphoma Expert Anas Younes, MD at 2019 Annual Gala on September 26 | PRWeb | 7/23/2019

… of Renowned Lymphoma Expert During National Blood Cancer Awareness Month 2019 LRF Gala Distinguished Leadership Award recipient, Anas Younes, MD (Memorial Sloan Kettering Cancer Center) The Foundation is critical to helping advance research and improved … patients through education.” The Lymphoma Research Foundation will also honor Genentech with this year’s Corporate Leadership Award in recognition of being pioneers in drug development, improving patient outcomes and nearly a decade of supporting the …

Memorial Sloan Kettering Cancer Center

Lymphoma Research Foundation to Honor Leading Lymphoma Expert Anas Younes, MD at 2019 Annual Gala on September 26 | PRWeb | 7/23/2019

… of Renowned Lymphoma Expert During National Blood Cancer Awareness Month 2019 LRF Gala Distinguished Leadership Award recipient, Anas Younes, MD (Memorial Sloan Kettering Cancer Center) The Foundation is critical to helping advance research and improved … patients through education.” The Lymphoma Research Foundation will also honor Genentech with this year’s Corporate Leadership Award in recognition of being pioneers in drug development, improving patient outcomes and nearly a decade of supporting the …

ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads | FierceBiotech | 5/31/2019

… next-gen treatments, namely California biotech Atara Biotherapeutics’ work on mesothelin-targeted CAR-T. This therapy, being researched with the Memorial Sloan Kettering Cancer Center, has shown glimpses of promise in a hard-to-treat … in the oncology and hematology global clinical development teams at Genentech. Berger arrives at a time when Reed, who joined Sanofi in July 2018, is starting to reshape the R&D group in line with …

Massachusetts General Hospital

Global Neoantigen Targeted Therapies Market 2019-2030: Marketed and Development Pipeline, Pipeline Analysis, List of Drug Developers | PR Newswire | 8/6/2019

… European Investment Bank Evaxion Biotech F-Prime Capital Fidelity Investments Flow Pharma Forbion Foresite Capital Franklin Advisers Frazier Healthcare Partners Genentech Geneos Therapeutics Genocea Biosciences Georgetown University GlobeImmune Google Ventures Gradalis Grey Wolf Therapeutics Gritstone … Level One Partners Likang Life Sciences Lilly Asia Ventures LSP Massachusetts General Hospital MaSTherCell Mateon Therapeutics Max Delbrck Center for Molecular Medicine in the Helmholtz Association MD Anderson Cancer Center Medigene MedImmune Meir Medical Center …

Immune Therapy A Great Tool, But Limitations Exist | WebMD | 6/13/2019

… tumors. Breast cancer had been looking even more promising. In March, the FDA approved checkpoint inhibitor Tecentriq, from biotech company Genentech, to treat metastatic triple-negative breast cancer, which is often lethal. But in one … checkpoint inhibitors, say Keith Flaherty, MD, a melanoma specialist at Massachusetts General Hospital in Boston. Roughly another third of melanoma patients get great early results, but then the drugs stop working, Flaherty says. The tumor …

Harvard Medical School

The Broad Institute launches academic-industrial consortium for cancer dependency studies and therapeutic development | PR Newswire | 7/17/2019

… and pharmaceutical industries have already joined the DepMap Consortium, including: AbbVie Astra-Zeneca Bayer Bristol- Myers Squibb Calico Life Sciences Genentech, a member of the Roche Group GlaxoSmithKline H3 Biomedicine Janssen Biotech, Inc. Repare Therapeutics … member in the Broad Cancer Program, professor of medicine at Harvard Medical School , chief research strategy officer at Dana-Farber Cancer Institute, and a faculty co-director of the DepMap project. “Our partners will gain …

The Galien Foundation Debuts 2019 Prix Galien USA Nominees in “Best Biotechnology Product,” “Best Pharmaceutical Product,” and “Best Medical Technology” Categories | PR Newswire | 7/15/2019

… Inc. Andexxa® Portola Pharmaceuticals, Inc. Dupixent® Regeneron & Sanofi ELZONRIS® Stemline Therapeutics, Inc. Emgality® Eli Lilly & Co. GALAFOLD® Amicus Therapeutics Hemlibra® Genentech, Inc. LUXTURNA™ (voretigene neparvovec-rzyl) Spark Therapeutics ONPATTRO® Alnylam Pharmaceuticals OXERVATE™ Dompé Pharmaceuticals Palynziq … CEO and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School , Cambridge, MA Joseph GOLDSTEIN , M.D., Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, University of Texas, Southwestern Medical Center , Dallas, TX …

Mayo Clinic

Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Business & Finance | heraldchronicle.com | PR Newswire | 8/26/2019

… The trial is being conducted at three prestigious cancer centers: USC Norris Comprehensive Cancer Center, Hoag Cancer Center and The Mayo Clinic. Trovagene has an ongoing Phase 1b/2 clinical trial of onvansertib in combination … Array (recently acquired by Pfizer), Ignyta (acquired by Roche) and Genentech. About Trovagene, Inc. Trovagene is a a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the …

MD Anderson Cancer Center

Biotech leaders speak out against dismissals of Chinese scientists - FierceBiotech (1 visits) | 8/22/2019

China’s theft of intellectual property from the U.S. and other countries isn’t new—remember the Genentech scientists and the GlaxoSmithKline researchers who funneled trade secrets to associates in China and Taiwan? But a government crackdown … well-publicized dismissal of five scientists—all Asian-American—from MD Anderson Cancer Center and Emory University . Other universities have fired researchers quietly, in cases that have stayed confidential, Michael Lauer, head of NIH’s extramural

Biotech leaders speak out against dismissals of Chinese scientists | FierceBiotech | 8/22/2019

China’s theft of intellectual property from the U.S. and other countries isn’t new—remember the Genentech scientists and the GlaxoSmithKline researchers who funneled trade secrets to associates in China and Taiwan? But a government crackdown … well-publicized dismissal of five scientists—all Asian-American—from MD Anderson Cancer Center and Emory University . Other universities have fired researchers quietly, in cases that have stayed confidential, Michael Lauer, head of NIH’s extramural

Kaiser Permanente

Merkley hears earful about cost, complexity of prescription drugs | 9/7/2019

Genentech, the manufacturer, is willing to give it to her for free — but Kaiser Permanente will not accept that arrangement. (Merkley’s staff has intervened. and Merkley said he hopes there can be an agreement.) “My hope is that I can support some kind of narrative to promote change,” Savara said. “I think of myself as pretty savvy. I am a medical social worker with a graduate degree, and I thought …

Why one patient could have gotten her meds for free but her insurer said no | The Business Journals | 8/27/2019

… said. “I’m not in poverty, but I’m not making enough to live comfortably with this condition and the prescription.” Luckily, Genentech offered her its drug for free. But Kasier vetoed that idea, Savara said. “I … dance. You’re spending a lot of time advocating for yourself.” Kaiser Permanente spokesman Michael Foley said if a member doesn’t qualify for its financial assistance programs, they may still be able to access a payment …

Cleveland Clinic

Debbie’s Dream Foundation and Cleveland Clinic Florida to Host 1st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast | PR Newswire | 8/30/2019

WESTON, Fla. , Aug. 30, Debbie’s Dream Foundation: Curing Stomach Cancer (DDF), in collaboration with Cleveland Clinic Florida, will host the 1 st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast featuring a panel … Astellas Pharma and Merck; Silver Sponsor Baptist Health; Bronze Sponsor Genentech; and National Supporting Sponsor Taiho Oncology. All lectures will be accessible on the DDF website at http://www.DebbiesDream.org/portal/ lecture-library . About Debbie’s Dream

Congress ramps up on surprise billing, competition and patents | Modern Healthcare | 6/8/2019

Cleveland Clinic Innovations, Genentech and Johnson & Johnson. June 12: Sick of surprise medical bills? So are lawmakers apparently. The House Energy and Commerce Committee’s health subcommittee will discuss how to protect patients from the costly and unexpected charges. June 12: How is vertical integration affecting healthcare competition? That’s the question the Senate Judiciary Committee’s antitrust subcommittee will ask in a hearing Wednesday. Three professors and one consultant will testify on …

Cleveland Clinic, Cleveland OH

Debbie’s Dream Foundation and Cleveland Clinic Florida to Host 1st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast | PR Newswire | 8/30/2019

WESTON, Fla. , Aug. 30, Debbie’s Dream Foundation: Curing Stomach Cancer (DDF), in collaboration with Cleveland Clinic Florida, will host the 1 st Annual Collaborative International Gastric Cancer Education Symposium and Live Webcast featuring a panel of leading oncologists and healthcare experts from around the world. The event will take place on Saturday, November 9, 2019 , from 8 a.m. to 5 p.m. at Cleveland Clinic in Weston, Florida , and will be …

Congress ramps up on surprise billing, competition and patents | Modern Healthcare | 6/8/2019

Print Getty Images June 10-12: The American Medical Association’s annual meeting rolls on in Chicago with additional business sessions and the inauguration of Dr. Patrice Harris as the group’s president Tuesday night. Harris intends to ramp up the association’s attention to mental health, equity of care and adverse childhood events. To read more about her priorities, check out our Q&A on p. 32 of this week’s issue. June 11 …

Clover Health

Medicare Advantage startup Clover Health launches drug development arm | MedCity News | 7/11/2019

The company has signed an initial partnership with Genentech that will focus on understanding the genetic components that are related to a person’s risk of developing ocular diseases like macular degeneration. Post a comment / at 5:22 PM Shares 0 Medicare Advantage startup Clover Health has started a biopharmaceutical division called Clover Therapeutics meant to use data on the insurance plans’ members to help inform the development of new therapies for …

Clover Health launches drug development subsidiary | FierceHealthcare | 7/11/2019

Startup Medicare Advantage (MA) insurer Clover Health has launched a new drug development subsidiary called Clover Therapeutics. The new arm launched alongside its first partnership, a research collaboration with Roche subsidiary Genentech that will focus on the genetic factors that can put people at risk for developing ocular diseases, Clover announced . “Clover Therapeutics was created to address the significant unmet needs in chronic progressive diseases in the Medicare population,” Cheng …

Aetna

The Seven Practices of Mindful Leaders | Forbes | 6/26/2019

… AETNA, LinkedIn, Genentech, Kaiser Permanente and others are exploring the benefits of mindfulness for developing their leaders, engaging their employees and transforming cultures. At a leader level, my executive coaching clients that achieve the highest sustained growth are those that incorporate mindfulness in their learning. Marc Lesser has taught his proven 7-step method to leaders at Google, Genentech, SAP, Facebook, and dozens of other Fortune 500 companies for over …

How a top VC went from carrying Steve Jobs’ bags during the Apple IPO to betting on companies that can lower costs and make going to the doctor less terrible | Business Insider | 4/18/2019

… Quist, a boutique investment bank in the Bay Area that worked on IPOs for Apple and for the biotech giant Genentech. Watching those companies go public got Lamont excited about entrepreneurs. So a year and … and health savings account company Payflex, which later sold to Aetna. The team started looking into investments like primary care company One Medical. Then came the Affordable Care Act, sparking a wave of new healthcare …

Sandra Horning

Chutes & Ladders—Garraway will take over as Roche’s next CMO | FierceBiotech | 8/23/2019

Genentech veteran Sandra Horning , who is retiring on the last day of this decade. In a very brief release , the Swiss Big Pharma said Garraway comes on board from the start of October, with the two working at the Big Pharma until Dec. 31, when Horning officially leaves. FierceBiotech Ousted AveXis CSO denies wrongdoing in Novartis data scandal, taps Musk lawyer AveXis Ousted CSO Brian Kaspar has denied wrongdoing in …

James Sabry

On a roll, Genentech inks discovery deals with Skyhawk, Convelo | FierceBiotech | 7/16/2019

Looks like someone ate their Wheaties. Genentech started Tuesday with a $1 billion biobucks deal with GPCR specialist Sosei Heptares and before the morning was out followed it with two more: one focused on cancer … represents a novel approach for difficult-to-treat diseases,” said James Sabry, M.D., Ph.D., global head of pharma partnering at Roche, in the statement. “Skyhawk has developed unique expertise in splicing biology, and we are

Dietmar Berger

Chutes & Ladders—Novartis’ Kymriah head jumps ship to Atara | FierceBiotech | 5/31/2019

… gene therapy lead to take the helm at Tmunity. The news also comes as Atara’s global head of R&D, Dietmar Berger , resigns to serve as head of development at Sanofi after one year in … rising through the oncology ranks at Amgen, Bayer and finally Genentech, where was a senior VP of the Roche unit. One year ago, Berger joined the exodus to biotech, joining Atara as global head of …

Sanofi hires ex-Genentech SVP Berger to head development | FierceBiotech | 5/30/2019

Sanofi has hired Dietmar Berger as head of development. Berger, a cancer specialist, ended his brief stint in biotech earlier this month to return to Big Pharma R&D at Sanofi. Berger spent almost 20 years rising through the oncology ranks at Amgen, Bayer and Genentech, culminating in him holding a senior vice president position at the Roche unit. One year ago, Berger joined the exodus from Big Pharma to …

Warren Buffett

Validea’s Top Five Healthcare Stocks Based On Martin Zweig - 8/18/2019 - Nasdaq.com | 8/18/2019

… multiple sclerosis ( MS ), FUMADERM severe plaque psoriasis and SPINRAZA spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN non-Hodgkin’s … who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here …

Malcolm Weir

Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum | PR Newswire | 9/12/2019

… de Graaf , Director, Head of Computational Chemistry R&D Pipeline Update – Translating Cutting-edge Science into New Drug Candidates – Dr. Malcolm Weir , EVP, Chief R&D Officer The event took place from 9:30-12:30 JST at … cancer (with AstraZeneca). Our additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK . “Sosei Heptares” is …

Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership | PR Newswire | 8/5/2019

… global rights to develop and commercialize therapeutic agents for each novel target through specified pharmacological approaches in the collaboration. Dr. Malcolm Weir , Executive VP and Chief R&D Officer of Sosei Heptares, said: “Takeda and … cancer (with AstraZeneca). Our additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK . “Sosei Heptares …

Kim Branson

Chutes & Ladders—Gilead CEO continues top-level revamp with 3 more exec exits | FierceMedicalDevices | 7/18/2019

Kim Branson from Genentech to oversee its artificial intelligence efforts to mine data for novel drug targets. Branson headed up AI at Genentech’s early clinical development unit for about a year before joining GSK as global head of AI and machine learning. The appointment is the latest in a series designed to revitalize its R&D operations through technology. FierceBiotech Evoke continues to expand with the hire of Jennifer O’Dwyer …

Severin Schwan

Changes in Roche’s Board of Directors and Corporate Executive Committee | Globe Newswire | 6/11/2019

… by Barbara Schädler (57), currently Head of Communications and Public Affairs at E.ON SE. Barbara Schädler will report to CEO Severin Schwan as a member of the enlarged Corporate Executive Committee. Severin Schwan: “Michael Heuer … in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more …

Merck raises stakes in lung cancer as rivals close in | Reuters | 12/11/2017

… market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments. Roche Chief Executive Severin Schwan said the Swiss company has “the potential to get into the lead in … serious side effects. Sandra Horning, chief medical officer at Roche’s Genentech unit, said survival results are expected in the first quarter of 2018. Bristol and AstraZeneca also expect to report data from key lung cancer …

John Reed

ASCO: Sanofi’s anti-CD38 combo boosts responses, extends lives in advanced multiple myeloma | FierceBiotech | 6/2/2019

… get treated, they go into remission, and then they relapse, get treated and go into remission,” Sanofi R&D head John Reed told FierceBiotech. “[Pom-dex] is usually the third line, when they’ve already been … highly reflective of real-world practice.” RELATED: Sanofi hires ex-Genentech SVP Berger to head development An analysis showed that the isatuximab combo performed similarly in different subgroups, including the elderly and people with poor …

Hal Barron

GSK hires Branson from Genentech to boost AI team | FierceMedicalDevices | 7/11/2019

GlaxoSmithKline has bolstered its artificial intelligence team by hiring Kim Branson from Genentech. The appointment gives Branson oversight of GSK’s efforts to use AI to find novel drug targets. Branson headed up AI at Genentech’s … up with a growing pool of Genentech alumni led by Hal Barron. Some of the changes made to GSK’s R&D group under Barron and Walmsley have related to AI. Months after Walmsley took over

GSK hires Branson from Genentech to boost AI team | FierceBiotech | 7/11/2019

GlaxoSmithKline has bolstered its artificial intelligence team by hiring Kim Branson from Genentech. The appointment gives Branson oversight of GSK’s efforts to use AI to find novel drug targets. Branson headed up AI at Genentech’s … up with a growing pool of Genentech alumni led by Hal Barron. Some of the changes made to GSK’s R&D group under Barron and Walmsley have related to AI. Months after Walmsley took over

Terry Rosen

Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer | Business & Finance | heraldchronicle.com | Business Wire | 6/24/2019

… product candidates through clinical studies to potentially expand access broadly to all patients who may benefit from these therapies,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “His insights into identifying underserved patient populations … new medicines during an approximately 14-year tenure with Roche/Genentech. From 2015-2017, Mr. Hoefer co-led the creation of Roche’s Phase 1b/2 IO platform (MORPHEUS) to adaptively assess and accelerate novel combination approvals …

Arcus hires ex-AbbVie, Genentech researcher as CMO | FierceMedicalDevices | 5/2/2019

… of William Grossman’s appointment alongside details of a deal with Strata Oncology. (Pixabay) Arcus Biosciences has named ex-AbbVie and Genentech employee William Grossman as chief medical officer. Grossman joins the immuno-oncology biotech as … cancer patients otherwise not benefiting from this therapeutic class,” CEO Terry Rosen said in a statement. Read more on …